JPRN-UMIN000036625已完成未知
Prognostic and predictive factors of lenvatinib in patients with hepatocellular carcinoma - Prognostic and predictive factors of lenvatinib in patients with hepatocellular carcinoma
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Others,meta-analysis etc
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Cases with a history of hypersensitivity to the ingredients of this drug 2) Patients who have been treated with other molecule-targeted drugs 3) Women who are pregnant, have a possibility of becoming pregnant, fall within 28 days postpartum, or breastfeeding. A man who wants a partner's pregnancy. 4) A case in which a mental illness or mental disorder that interferes with daily life is included and it is judged that participation in research is difficult 5) Cases judged as inappropriate for this study by the principal investigator
研究者
相似试验
招募中
不适用
Retrospective study for Lenvatinib for unresectable thyroid cancersnresectable thyroid cacersJPRN-UMIN000030969Kyoto Prefectural University of Medicine50
招募中
Unknown
Efficacy and safety of lenvatinib for patients with advanced or recurrent thymic carcinoma: A real-world retrospective studynresectable advanced or recurrent thymic carcinomaJPRN-UMIN000051645Graduate School of Medicine, Chiba University80
招募中
不适用
The study of efficacy of lenvatinib in patients with hepatocellular carcinoma(HCC): Multicenter analysis.Hepatocellular carcinomaJPRN-UMIN000037054Yokohama City University Medical Center250
已完成
不适用
The safety and efficacy of Lenvatinib for patients with unresectable hepatocellular carcinoma on practical medicine after the approvalHepatocellular carcinomaJPRN-UMIN000034333ational Hospital Organization Kyoto Medical Center500
进行中（未招募）
1 期
A phase II study to evaluate the safety and efficacy of lenvatinib in patients with advanced grade 1/2 neuroendocrine neoplasmas of pancreatic and extrapancreatic origin.EUCTR2015-001467-39-ITGETNE (GRUPO ESPAñOL DE TUMORES NEUROENDOCRINOS)110